Study links in ovo silver nanoparticles to broiler gains: full analysis

A new Animals paper published April 28, 2026, says in ovo silver nanoparticle administration may improve broiler performance after hatch, with the clearest benefits seen at 15 ppm. In the study, researchers injected Cobb500 eggs on day 18 of incubation and reported gains in hatchability, body weight, feed conversion, antioxidant activity, and immune-related markers compared with control groups. (mdpi.com)

The work fits into a longer-running line of poultry research on in ovo supplementation, where nutrients or bioactive compounds are delivered before hatch to support embryonic development and the transition to feed intake after hatch. Earlier studies have suggested silver nanoparticles can modulate immune gene expression or improve some post-hatch immune responses, though prior findings have been mixed on whether those effects translate into consistent growth benefits. A 2017 PubMed-indexed study, for example, found day-18 in ovo silver nanoparticle supplementation improved immune response without materially affecting hatchability or growth performance, while a 2015 MDPI paper reported improved immunocompetence in embryos. (pubmed.ncbi.nlm.nih.gov)

In the new trial, 300 fertilized eggs were divided into five treatments: non-injected control, saline vehicle control, and silver nanoparticles at 10, 15, or 20 ppm. After hatch, 48 chicks per treatment were followed for 35 days. According to the abstract and journal listing, birds from silver nanoparticle-treated eggs showed improved body weight, body weight gain, and feed conversion ratio, along with lower feed intake. The researchers also reported higher hemoglobin, packed cell volume, growth hormone, serum proteins, antioxidant enzyme activity, lysozyme activity, complement 3, and cytokine concentrations, with lower malondialdehyde, a marker associated with oxidative stress. Effects were described as dose-dependent, with 15 ppm generally performing best. (mdpi.com)

That said, the broader silver nanoparticle literature is more complicated than a single efficacy study can capture. Other poultry studies have looked at dietary or oral silver nanoparticle use and reported both potential benefits and safety concerns depending on formulation and dose. One recent broiler paper indexed in PubMed found promise for chitosan-coated silver nanoparticles, but also noted adverse tissue findings in birds given a higher silver nanoparticle dose without that coating. Separate studies have examined tissue retention and transfer of silver in poultry production, underscoring why food-chain fate remains a central question. (pubmed.ncbi.nlm.nih.gov)

I did not find a formal press release or on-record expert reaction tied specifically to this April 2026 paper. Still, the regulatory context is clear: FDA’s Center for Veterinary Medicine says it oversees animal foods and has separate guidance for industry on the use of nanomaterials in food for animals, while EFSA maintains dedicated guidance on assessing small particles and nanomaterials in the food and feed chain. In practical terms, that means enthusiasm around performance or immune outcomes is likely to be tempered by questions about characterization, exposure, residues, and safety before any field use could move toward commercialization. (fda.gov)

Why it matters: For veterinarians and poultry health teams, the study is notable because it points to a possible hatchery-stage intervention that could affect both production metrics and immune readiness downstream. If reproducible, that combination would be commercially attractive in a sector still looking for tools that support resilience and efficiency without relying on traditional antimicrobial strategies. But veterinary professionals should read this as hypothesis-building evidence, not a signal to adopt. The study appears to focus on short-term physiological and performance outcomes, and it does not resolve the issues that matter most for real-world use: repeatability across flocks, compatibility with hatchery workflows, residue depletion in edible tissues, environmental release, and regulator acceptance. (mdpi.com)

There’s also a translational gap between experimental in ovo injection and commercial deployment. Hatchery interventions have to be scalable, consistent, and safe at very large volumes, and nanomaterials add another layer of scrutiny around manufacturing specifications and particle characterization. Even if the biological signal is real, veterinary decision-makers will want independent replication, larger field studies, and a clearer safety package before treating silver nanoparticles as more than an experimental platform. (fda.gov)

What to watch: The next milestones are likely to be confirmatory trials, residue and toxicology work, and any indication that regulators or poultry integrators are engaging with silver nanoparticle in ovo approaches in a formal development pathway. Until then, this looks most important as a research marker in the broader push to shape chick performance and immunity before hatch, rather than as an imminent change in veterinary or hatchery practice. (mdpi.com)